세계의 혈전 치료 시장 예측(-2030년)

Market Overview

The thrombus treatment market is projected to enroll a solid CAGR of 6.84% during the conjecture time frame. The elements impacting the market development are the rising rate of injury cases and the rising reception of a stationary way of life supporting the market development.

Injury is viewed as one of the most widely recognized reasons for the arrangement of thrombus in the lower limits. At the point when any veins get harmed, the encompassing blood thickens and frames a coagulation. Subsequently, vein harm because of injury can cause the development of a thrombus. The expanded number of injury cases, particularly street mishaps has prompted an expansion popular of thrombus treatment. As per the WHO in June2018, around 1.3 million individuals lose their lives because of street mishaps universally. Moreover, there were 178 million new break cases enlisted in 2019 worldwide which had expanded by 33.4% beginning around 1990. The absolute pervasiveness of intense and long-haul break side effects had reached 455 million of every 2910 with an increment of 67.5% starting around 1990. The break is one more typical reason for apoplexy. Consequently, the rising occurrence of injury cases is driving market interest in Thrombus Treatment.

Market Segmentation

Atrial and venous thrombus are the two market segments for thrombus treatment, respectively. Right atrial thrombus and left atrial thrombus were formed from the atrial thrombus.

Data on the thrombus treatment market has been divided into treatment categories such as medicinal therapy, surgery, and others. Thrombolytics, antiplatelets, and anticoagulants make up the medical therapy component.

Regional Analysis

North America held the biggest market share and contributed USD 16.19 billion of every 2021 attributable to created medical care foundation, research awards for delivering protected and powerful thrombus treatment, and the developing matured and large populace in the region.

Europe's thrombus treatment market represents the second-biggest market share attributable to the developing examination and treatment of profound vein apoplexy and developing mindfulness with respect to thrombus difficulties are the central point driving the market development in Europe. For example, as per the article distributed in Public Community for Biotechnology Data (NCBI), profound vein apoplexy (DVT) is a medical services trouble in Europe.

The Asia-Pacific thrombus treatment market is supposed to develop at a critical share from2018 to 2030. Attributable to the presence of an enhanced patient pool, the rising pervasiveness of profound vein apoplexy, and expanding mindfulness about the treatment and utilization of medications to treat different apoplexy occasions in nations, for example, China and India are probably going to support the market in the Asia-Pacific region. In addition, China market of thrombus treatment held the biggest market share, and the India market of thrombus treatment is the quickest developing market in the Asia-Pacific region.

Major Players

Key companies in the Thrombus Treatment Market includes Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), and Bayer AG (Germany).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCE OF TRAUMA CASES
  • 4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLE
• 4.3 RESTRAINTS
  • 4.3.1 RISKS ASSOCIATED WITH THROMBOSIS DRUGS
• 4.4 OPPORTUNITIES
  • 4.4.1 NEW PRODUCT APPROVALS AND LAUNCHES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION AND SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL THROMBUS TREATMENT MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON PRODUCTION
  • 5.3.3 DEMAND-SUPPLY GAP ANALYSIS
  • 5.3.4 IMPACT ON PRICING
• 5.4 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM

6 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 ATRIAL THROMBUS
• 6.3 VENOUS THROMBUS

7 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT

• 7.1 OVERVIEW
• 7.2 MEDICAL THERAPY
• 7.3 SURGERY
• 7.4 OTHERS

8 GLOBAL THROMBUS TREATMENT MARKET, BY REGION

• 8.1 OVERVIEW
  • 8.1.1 NORTH AMERICA
    • 8.1.1.1 US
    • 8.1.1.2 CANADA
  • 8.1.2 EUROPE
    • 8.1.2.1 GERMANY
    • 8.1.2.2 UK
    • 8.1.2.3 FRANCE
    • 8.1.2.4 ITALY
    • 8.1.2.5 SPAIN
    • 8.1.2.6 REST OF EUROPE
  • 8.1.3 ASIA-PACIFIC
    • 8.1.3.1 JAPAN
    • 8.1.3.2 CHINA
    • 8.1.3.3 INDIA
    • 8.1.3.4 AUSTRALIA
    • 8.1.3.5 SOUTH KOREA
    • 8.1.3.6 REST OF ASIA-PACIFIC
  • 8.1.4 REST OF THE WORLD
    • 8.1.4.1 MIDDLE EAST
    • 8.1.4.2 AFRICA
    • 8.1.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL THROMBUS TREATMENT MARKET
• 9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL THROMBUS TREATMENT MARKET
• 9.5 KEY DEVELOPMENT ANALYSIS
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES
  • 9.6.2 PARTNERSHIP/COLLABORATION
• 9.7 MAJOR PLAYERS FINANCIAL MATRIX
  • 9.7.1 SALES (USD MILLION), 2021
  • 9.7.2 R&D (USD MILLION), 2021

10 COMPANY PROFILES

• 10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL ANALYSIS
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 SANOFI
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 PFIZER INC.
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 SWOT ANALYSIS
  • 10.3.6 KEY STRATEGIES
• 10.4 BAYER AG
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 ANGIODYNAMICS.
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 KEY STRATEGIES
• 10.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 BRISTOL-MYERS SQUIBB COMPANY
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 KEY STRATEGIES
• 10.8 ASPEN HOLDINGS
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 JOHNSON & JOHNSON SERVICES, INC.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 SWOT ANALYSIS
  • 10.9.6 KEY STRATEGIES
• 10.10 DAIICHI SANKYO COMPANY, LIMITED
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS